0.18
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Ampio Pharmaceuticals
Its shares trade under the ticker AMPE. It has been listed since 19 May 2011. In the fiscal year to 31 December 2015, it reported revenue of $1.2m and a net loss of $32.0m. At that date it held total assets of $50.4m and shareholders' equity of $37.0m.
Ampio Pharmaceuticals, Inc. is a biopharmaceutical company that engages in the development of therapies to treat prevalent inflammatory conditions. The company is headquartered in Englewood, Colorado. The company went IPO on 2011-05-19. The firm is focused primarily on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The firm's two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema. Ampion is a sub 5000 molecular weight fraction of commercial human serum albumin (HSA). Optina is a low-dose formulation of danazol. The Ampio segment consists of its biopharmaceuticals compounds and the clinical trials associated with them. The firm is primarily developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process, and decreasing vascular permeability.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 19 May 2011
- Employees
- 23
- Website
- ampiopharma.com ↗
Leadership
Pay as last reported
- Mr. J. Kevin BuchiIndependent Chairman of the Board$99,500
- Mr. Michael MartinoChief Executive Officer, Director, since 2021$550,000
- Mr. Daniel StokelyChief Financial Officer, Secretary$338,315
- Ms. Elizabeth JobesIndependent Director$64,500
- Dr. David StevensIndependent Director$65,500
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 35
- Environment
- 33
- Social
- 32
- Governance
- 41
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Ampion for osteoarthritis of the knee targets prevalent inflammatory conditions with limited treatment options.
- Optina for diabetic macular edema uses a low-dose danazol formulation for effective therapy.
- Ampio Pharmaceuticals focuses on biopharmaceuticals with specific pathways at protein expression level.
Weaknesses
- Ampio Pharmaceuticals has only 23 employees, indicating limited workforce capacity.
- The company's two lead product candidates are in development phase without commercialization.
- Ampio's clinical trials are associated with biopharmaceutical compounds requiring significant investment.
Opportunities
- Ampio Pharmaceuticals can expand its focus on inflammatory conditions with limited treatment options.
- The firm's biopharmaceuticals segment offers potential for new therapies in Health Care sector.
- Ampio's development of Ampion and Optina may attract partnerships in Pharmaceuticals industry.
Threats
- Ampio Pharmaceuticals faces competition from established biopharmaceutical companies in Health Care.
- The company's reliance on two lead product candidates poses a risk if clinical trials fail.
- Ampio's limited workforce of 23 employees may hinder rapid development and market entry.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.